NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer – Nanotechnology News Today – EIN Presswire
Trusted News Since 1995
A service for nanotechnology industry professionals
·
Tuesday, December 27, 2022
·
608,321,929
Articles
·
3+ Million Readers
